{"brief_title": "Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)", "brief_summary": "To assess the tolerability and safety of hOKT3g1 (Ala-Ala) after a 12-day dosing regimen administered via intravenous infusion. To assess the pharmacokinetics of hOKT3g1 (Ala-Ala).", "condition": ["Diabetes Mellitus, Insulin-Dependent"], "intervention_type": ["Drug"], "intervention_name": ["hokt3g1 (ALA-ALA)"], "criteria": "To be eligible - participants will have Type 1 diabetes, diagnosed within the previous 12 months and established by standard American Diabetes Association criteria. - All participants will have autoantibodies: either anti-GAD65, anti-ICA512, or if treated with insulin for less than 7 days, anti-insulin. - The age range will be between 8 and 30 years; and - a minimum weight of 34 kg.", "gender": "All", "minimum_age": "8 Years", "maximum_age": "30 Years", "healthy_volunteers": "Accepts Healthy Volunteers", "mesh_term": ["Diabetes Mellitus", "Diabetes Mellitus, Type 1"], "id": "NCT00073255"}